You are here: Industry Insights > Market News > Glenmark Pharma receives USFDA approval for Sirolimus tablets

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

Hot Products

Propantheline Bromide

carbomer 974P

Coenzyme Q10

Refined Fish Oil

Black Currant Extract

Hydrocortisone

Glenmark Pharma receives USFDA approval for Sirolimus tablets

expresspharmaOctober 21, 2020

Tag: Glenmark , Sirolimus tablets , FDA

Favorites

Glenmark Pharmaceuticals has received final approval by the United States Food & Drug Administration (US FDA) for Sirolimus Tablets, 0.5 mg, 1 mg and 2 mg, the generic version of Rapamune Tablets, 0.5 mg, 1 mg and 2 mg, of PF Prism CV.

According to IQVIA sales data for the 12 month period ending August 2020, the Rapamune Tablets, 0.5 mg, 1 mg and 2 mg market achieved annual sales of approximately $119.7 million.

Glenmark’s current portfolio consists of 165 products authorised for distribution in the US marketplace and 45 ANDA’s pending approval with the US FDA.

Previous:Zydus Cadila gets tentative USFDA nod for Tofacitinib ER tablets

Next:CordenPharma Colorado Completes Highly Potent API Lab Expansion

Vetter Wins Best Managed Companies Award 2024

Biotech NewswireMay 30, 2024

Vetter, a globally leading Contract Development and Manufacturing Organization (CDMO), has once again been awarded the Best Managed Companies Award, marking its fifth consecutive win.

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

Biotech NewswireMay 30, 2024

New CRO Focused on Cannabis-based Drug Trials Launched

Biotech NewswireMay 23, 2024

Glenmark Pharma receives USFDA approval for Sirolimus tablets | Pharmasources.com

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

PharmaSourcesMay 21, 2024

The first patient has been dosed in a clinical trial of the Company's BCL2 inhibitor, ICP-248, in combination with orelabrutinib as a first-line therapy for chronic lymphocytic leukemia /small lymphocytic lymphoma (CLL/SLL) in China.

Glenmark Pharma receives USFDA approval for Sirolimus tablets

Related News

Vetter Wins Best Managed Companies Award 2024

ModeX Therapeutics Leverages ProBioGen's Expertise for Accelerated COVID-19 Antibody Development

New CRO Focused on Cannabis-based Drug Trials Launched

InnoCare Announces First Patient Dosed in Clinical Trial of BCL2 Inhibitor ICP-248 in Combination with Orelabrutinib as First-Line Therapy for Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma

You may like